AAV Immunotoxicity: Implications in Anti-HBV Gene Therapy.

ABSTRACT: Hepatitis B virus (HBV) has afflicted humankind for decades and there is still no treatment that can clear the infection. The development of recombinant adeno-associated virus (rAAV)-based gene therapy for HBV infection has become important in recent years and research has made exciting leaps. Initial studies, mainly using mouse models, showed that rAAVs are non-toxic and induce minimal immune responses. However, several later studies demonstrated rAAV toxicity, which is inextricably associated with immunogenicity. This is a major setback for the progression of rAAV-based therapies toward clinical application. Research aimed at understanding the mechanisms behind rAAV immunity and toxicity has contributed significantly to the inception of approaches to overcoming these challenges. The targ

SUBMITTER: Jacobs R 

PROVIDER: S-EPMC10745739 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature